LATEST ARTICLES
China
AnJie Broad Law Firm
《专利法》第七十六条、《药品专利纠纷早期解决机制实施办法（试行）》（简称药品专利纠纷实施办法）和《最高人民法院关于审理申请注
Greenberg Traurig, LLP
In December 2023, China's National Healthcare Security Administration (NHSA) published the 2023 National Reimbursement Drug List (2023 NRDL), implementing a comparable level of pricing discounts...
Kangxin
药品作为一种特殊商品，承载着千百万消费者的生命健康安全。国家对于药品的监管，犹如一位严谨的编辑，严格把关每一个细节。
Greenberg Traurig, LLP
In China, recent technological advances and legislative and regulatory developments that attempt to balance risk mitigation and innovation continue to reshape the life sciences sector in terms of cross-border...
CCPIT Patent & Trademark Law Office
A medical use of a product may relate to i) the use of a new drug to treat a disease ("first medical use"); ii) the use of a known drug to treat a new disease...
AnJie Broad Law Firm
互联网、大数据、人工智能等数字技术的创新应用，正快速改变传统医疗服务模式。而数字医疗除了受到传统医疗的法律规制，其数字化的特
AnJie Broad Law Firm
在此大背景下，我们团队根据近期观察与研究，从医药行业及法律行业的综合角度出发，对此次医药反腐行动的发展进程以及可能涉及的重点
Arnold & Porter
In recent years, China's current drug regulations and draft proposals have introduced a new requirement that foreign drug market authorization holders (MAHs) must designate...
Kangxin
長城戦略諮訊有限公司は20日、「中国ユニコーン企業研究報告書2023」（以下、「報告書」）を発表した。それによると、中国のユニコーン企ઊ
CCPIT Patent & Trademark Law Office
Article 10. 1. 7 of Trademark Law stipulates that signs that are deceptive and likely to cause the public to misrecognize the quality or origin of the goods shall not be registered and used as trademarks.
Nexdigm Private Limited
2023年 4月 26日、インド政府 （GOI）は 「 国家医療機器政策 2023」を承 認 し ました。
Ropes & Gray LLP
On June 1, 2023, China's Ministry of Science and Technology (the "MOST") issued the long-awaited Implementing Rules on the Administrative Regulations on Human Genetic Resources...
AFD China
On May 28, China's market regulator said it had fined two pharmaceutical companies 320 million yuan for entering into a monopolistic deal and abusing dominant market position.
AnJie Broad Law Firm
根据公开渠道查询的相关研究报告显示[1]，近年来中国基因检测企业的注册量保持在1800家至2000家之间，基因检测行业（包括消费级基因检测服务）&
Kangxin
哈爾浜（ハルビン）工業大学と哈爾浜医科大学の科学研究者が共同開発したクマムシ型医療用 マイクロナノロボットが、静脈高速血流環境
Arnold & Porter
On June 1, 2023, the Ministry of Science and Technology (MOST) issued the Implementation Rule for the Regulation on the Administration of Human Genetic Resources (the Implementation Rule)...
Goodwin Procter LLP
We first reported on MAILISHU's approval on Big Molecule Watch's China blog.
AFD China
A total of 115 technicians were appointed as investigators by Beijing Intellectual Property Court in February to help solve technical cases.
Arnold & Porter
On December 30, 2022, China's Ministry of Commerce (MOFCOM) published a proposed version of the Catalogue of Technologies Prohibited and Restricted from Export (Proposed Catalogue) for public comment...
Goodwin Procter LLP
This week, Bio-Thera Solutions announced that the China National Medical Products Administration (NMPA) has approved BAT1806, a biosimilar of ACTEMRA (tocilizumab).
Mondaq Webinars
APR24
FREE News Alerts
Sign Up for our free News Alerts - All the latest articles on your chosen topics condensed into a free bi-weekly email.
Comparative Guides
Upcoming Events
Mondaq Advice Centres
